Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CABA Cabaletta Bio	$1.99 +10.6%	$1.55	$0.99 ▼ $13.50	$100.98M	2.81	1.65 million shs	4.56 million shs
PLX Protalix BioTherapeutics	$1.49 -3.2%	$2.15	$0.82 ▼ $3.10	$118.61M	-0.21	557,304 shs	500,745 shs
PSTI Pluristem Therapeutics		$1.24	$0.95 ▼ $3.45	$32.35M	1.91	715,259 shs	2,128 shs
TARA Protara Therapeutics	$3.14 -3.7%	$3.49	$1.60 ▼ $10.48	$121.15M	1.34	774,791 shs	165,447 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CABA Cabaletta Bio	+10.56%	-19.76%	+53.08%	+9.34%	-83.63%
PLX Protalix BioTherapeutics	-3.25%	-5.70%	-10.78%	-33.48%	+25.74%
PSTI Pluristem Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
TARA Protara Therapeutics	-3.68%	-5.99%	+0.32%	-27.15%	+18.49%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CABA Cabaletta Bio	2.864 of 5 stars	4.5	1.0	0.0	0.0	3.1	0.8	0.6
PLX Protalix BioTherapeutics	2.6019 of 5 stars	3.5	4.0	0.0	0.0	0.6	0.0	1.9
PSTI Pluristem Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TARA Protara Therapeutics	2.4539 of 5 stars	3.6	2.0	0.0	0.0	3.5	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CABA Cabaletta Bio	3.00	Buy	$20.33	921.78% Upside
PLX Protalix BioTherapeutics	3.00	Buy	$15.00	906.71% Upside
PSTI Pluristem Therapeutics	0.00	N/A	N/A	N/A
TARA Protara Therapeutics	3.14	Buy	$20.50	552.87% Upside

Current Analyst Ratings Breakdown

Latest PSTI, PLX, TARA, and CABA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	CABA Cabaletta Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
5/22/2025	TARA Protara Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$21.00
5/16/2025	CABA Cabaletta Bio	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $13.00
5/15/2025	CABA Cabaletta Bio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$23.00 ➝ $25.00
4/28/2025	TARA Protara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/16/2025	TARA Protara Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$12.00
4/1/2025	CABA Cabaletta Bio	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$6.00 ➝ $3.00
4/1/2025	CABA Cabaletta Bio	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $7.00
4/1/2025	CABA Cabaletta Bio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/1/2025	CABA Cabaletta Bio	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$30.00 ➝ $22.00
4/1/2025	CABA Cabaletta Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	$5.51 per share	N/A
PLX Protalix BioTherapeutics	$59.76M	1.98	$0.08 per share	17.80	$0.47 per share	3.17
PSTI Pluristem Therapeutics	$20K	0.00	N/A	N/A	$1.80 per share	0.00
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	$6.01 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CABA Cabaletta Bio	-$67.68M	-$2.54	N/A	N/A	N/A	N/A	-50.10%	-45.49%	8/6/2025 (Estimated)
PLX Protalix BioTherapeutics	$8.31M	$0.04	N/A	4.81	N/A	-21.03%	-30.89%	-11.74%	N/A
PSTI Pluristem Therapeutics	-$49.87M	-$1.47	N/A	N/A	N/A	N/A	-100.63%	-55.46%	N/A
TARA Protara Therapeutics	-$40.42M	-$1.72	N/A	N/A	N/A	N/A	-55.96%	-49.06%	8/5/2025 (Estimated)

Latest PSTI, PLX, TARA, and CABA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	CABA Cabaletta Bio	-$0.67	-$0.71	-$0.04	-$0.71	N/A	N/A
5/9/2025	Q1	PLX Protalix BioTherapeutics	N/A	-$0.05	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	TARA Protara Therapeutics	-$0.47	-$0.29	+$0.18	-$0.29	N/A	N/A
3/31/2025	Q4 2024	CABA Cabaletta Bio	-$0.65	-$0.65	N/A	-$0.65	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	N/A	N/A	N/A	N/A
PSTI Pluristem Therapeutics	N/A	N/A	N/A	N/A	N/A
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CABA Cabaletta Bio	N/A	8.11	8.11
PLX Protalix BioTherapeutics	N/A	1.98	1.27
PSTI Pluristem Therapeutics	0.57	8.22	8.22
TARA Protara Therapeutics	N/A	9.85	9.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CABA Cabaletta Bio	N/A
PLX Protalix BioTherapeutics	16.53%
PSTI Pluristem Therapeutics	16.94%
TARA Protara Therapeutics	38.13%

Insider Ownership

Company	Insider Ownership
CABA Cabaletta Bio	11.25%
PLX Protalix BioTherapeutics	6.50%
PSTI Pluristem Therapeutics	5.40%
TARA Protara Therapeutics	8.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CABA Cabaletta Bio	50	50.74 million	44.05 million	Optionable
PLX Protalix BioTherapeutics	200	79.61 million	69.00 million	Optionable
PSTI Pluristem Therapeutics	153	32.35 million	30.60 million	Optionable
TARA Protara Therapeutics	30	38.58 million	18.05 million	Optionable

PSTI, PLX, TARA, and CABA Headlines

Recent News About These Companies

Two Sigma Investments LP Cuts Stock Holdings in Protara Therapeutics, Inc. (NASDAQ:TARA)

June 14 at 3:12 AM | marketbeat.com

Cantor Fitzgerald Forecasts TARA FY2026 Earnings

June 11 at 2:03 AM | americanbankingnews.com

Analysts Set Expectations for TARA FY2026 Earnings

June 10, 2025 | marketbeat.com

Chutes & Ladders—Protara gears up for next steps with commercial pro

June 7, 2025 | fiercebiotech.com

Protara Therapeutics, Inc. (NASDAQ:TARA) Position Increased by Bank of America Corp DE

June 7, 2025 | marketbeat.com

Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Recommendation of "Buy" by Analysts

June 5, 2025 | marketbeat.com

The Escalator: Digitas Health, Bristol Myers Squibb, Inizio Evoke and more

June 4, 2025 | mmm-online.com

Protara Therapeutics names new Chief Commercial Officer

June 4, 2025 | investing.com

Millennium Management LLC Purchases 357,051 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA)

June 3, 2025 | marketbeat.com

Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer

June 2, 2025 | globenewswire.com

Toronto Dominion Bank Acquires New Stake in Protara Therapeutics, Inc. (NASDAQ:TARA)

May 30, 2025 | marketbeat.com

Protara Therapeutics (NASDAQ:TARA) Earns Buy Rating from Analysts at Jones Trading

May 24, 2025 | marketbeat.com

BNP Paribas Financial Markets Purchases Shares of 151,906 Protara Therapeutics, Inc. (NASDAQ:TARA)

May 24, 2025 | marketbeat.com

Jones Trading Initiates Coverage of Protara Therapeutics (TARA) with Buy Recommendation

May 23, 2025 | msn.com

Toronto Dominion Bank Takes Position in Protara Therapeutics, Inc. (NASDAQ:TARA)

May 23, 2025 | marketbeat.com

Richard Levy Spends US$64k On Protara Therapeutics Stock

May 22, 2025 | finance.yahoo.com

Velan Capital Investment Management LP Buys 1,005,000 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA)

May 21, 2025 | marketbeat.com

Janus Henderson Group PLC Invests $11.94 Million in Protara Therapeutics, Inc. (NASDAQ:TARA)

May 19, 2025 | marketbeat.com

With 73% ownership, Protara Therapeutics, Inc. (NASDAQ:TARA) boasts of strong institutional backing

May 16, 2025 | finance.yahoo.com

Integral Health Asset Management LLC Makes New $7.39 Million Investment in Protara Therapeutics, Inc. (NASDAQ:TARA)

May 14, 2025 | marketbeat.com

J. Goldman & Co LP Takes $748,000 Position in Protara Therapeutics, Inc. (NASDAQ:TARA)

May 14, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSTI, PLX, TARA, and CABA Company Descriptions

Cabaletta Bio NASDAQ:CABA

$1.99 +0.19 (+10.56%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.96 -0.03 (-1.76%)

As of 06/13/2025 07:50 PM Eastern

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Protalix BioTherapeutics NYSE:PLX

$1.49 -0.05 (-3.25%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.51 +0.02 (+1.34%)

As of 06/13/2025 07:51 PM Eastern

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Pluristem Therapeutics NASDAQ:PSTI

Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.

Protara Therapeutics NASDAQ:TARA

$3.14 -0.12 (-3.68%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$3.14 +0.00 (+0.13%)

As of 06/13/2025 04:29 PM Eastern

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time